Feature | Breast Imaging | January 30, 2019 | By Jeff Zagoudis

Technologies to Watch in Breast Imaging

Rising prevalence of breast cancer and other chronic breast diseases, as well as more new technological innovations, will keep this technology on the forefront

Traditional mammography continues to be the gold standard for breast cancer screening technologies. However, use of 3-D breast tomosynthesis is growing rapidly.

Traditional mammography continues to be the gold standard for breast cancer screening technologies. However, use of 3-D breast tomosynthesis is growing rapidly.

Breast Imaging Sectra

Image courtesy of Sectra

The importance of early detection of breast cancer has been underscored in recent years as the breast health community learns more about breast density and risk models, turning toward personalized medicine. As this knowledge base expands, healthcare professionals are exploring the benefits of different imaging technologies to improve detection and save lives.

 

Mammography

Mammography continues to be the gold standard for breast cancer screening technologies, but recent discussions have debated how often women should be screened and/or the need for supplemental imaging.

In 2016, the U.S. Preventive Services Task Force (USPSTF) released controversial new recommendations for mammography screening practices. In addition to suggesting biennial screening is sufficient for women in their 40s — going against conventional wisdom — the task force posited the balance of benefits versus harms for mammography screening in women over age 75 was inconclusive.

A large study presented at the 2018 Radiological Society of North America (RSNA) annual meeting in November suggests that women over 75 do benefit from continuing screening, depending on their circumstances, due to a high incidence of breast cancer. The study, from Elizabeth Wende Breast Care in Rochester, N.Y., looked at more than 750,000 mammography exams performed between 2007 and 2017. A subset analysis of nearly 77,000 patients age 75 and older found a total of 645 malignancies in 616 patients for a cancer rate of 8.4 detections per 1,000 exams in this age group. The cancer rate for the entire patient cohort was only 5 detections per 1,000.

“We think it’s very important for women in their 70s to understand there is still benefit to annual screening mammography,” said Stamatia Destounis, M.D. “Right now in the United States, a 75-year-old woman may live another 10 years. If you’re in good enough health to be able to take care of your family and go to work and everything else, you can come in and have a screening mammogram that takes a few minutes.”

Destounis also noted that cancers found in the older age group were predominantly invasive (7 percent lymph node metastasis rate), evaluated as grade 2-3 lesions. You can watch a video, “Women Benefit From Mammography Screening Beyond Age 75,” with Destounis at https://bit.ly/2R7swTR.

One of the main reasons breast cancer screening has shifted to a more personalized approach in recent years is the further understanding of the role of fibroglandular breast density in masking cancer. On a conventional 2-D mammogram, both dense tissue and cancerous tissue appear white, making the cancer mammographically occult.

Quantitative assessment of breast density can improve cancer detection rates, as seen in an RSNA 2018 study. The case-control study of 1,204 U.K. women ages 50-74 assessed breast density using a visual analog scale of 0 to 100, BI-RADS 5th Edition density categories and fibroglandular volume (FGV) calculated by Volpara software. Study results showed that FGV predicted both screen-detected and interval cancers. The other methods predicted interval cancers but not screen-detected cancers.

 

Contrast-enhanced Spectral Mammography

Contrast-enhanced spectral mammography (CESM), or contrast-enhanced digital mammography (CEDM), has provided an alternative to traditional mammography since 2011 when the first CESM system was approved for the U.S. market. Contrast dye injected into the breast is often taken up by lesions, making them easier to spot.

A study presented at RSNA 2018 demonstrated that CEDM can help safely reduce the number of benign breast biopsies, which can cause physical pain and stress for patients. Under the current (5th) edition of the American College of Radiology’s Breast Imaging-Reporting and Data System (BI-RADS), if a detected lesion is classified as BI-RADS 4 or 5, a biopsy is recommended. An estimated 20-25 percent of BI-RADS 4 suspicious lesions do not turn out to be malignancies, however, making biopsies universal is not ideal at this level.

The study looked at 57 women (ages 34-74) with 60 BI-RADS 4A or 4B soft tissue lesions scheduled for ultrasound, stereotactic or tomosynthesis directed biopsy, and CEDM was performed immediately prior to biopsy. Four MQSA-qualified radiologists provided 3 BI-RADS scores for each lesion: mammography/digital breast tomosynthesis (DBT) only, with ultrasound added and with CEDM added.

Prior to CEDM, 72 percent of the ratings were classified as BI-RADS 4; after CEDM, 60 out of 240 total ratings were reclassified as less than BI-RADS 3.

 

Breast Ultrasound

For women with dense fibroglandular breast tissue, masking increases the likelihood that cancers could be missed on a mammogram. Ultrasound has offered an alternative, found to detect some 30 percent of cancers missed on mammography.

While breast ultrasound has proven effective in the short-term, little is known about its long-term performance. Destounis presented a second study at RSNA 2018 that tracked the performance of screening breast ultrasound over a five-year period at her clinic in New York.

The retrospective study assessed data from 23,878 screening ultrasound exams performed between 2013 and 2017 in patients with heterogeneously dense or extremely dense breasts. Destounis and her team were interested in the cancer detection rate (CDR), positive predictive value (PPV) and biopsy rate for lesions detected with ultrasound only.

Cancer detection rate did increase over the first three years of the study, from 1.4 cancers per 1,000 to 3.6 per 1,000, then decreased in 2016 and 2017 to 2.4/1,000 and 2.2/1,000, respectively. It should be noted that use of digital breast tomosynthesis (DBT) increased dramatically in the study population over the five-year period, from 18.7 percent in 2013 to 99.3 percent in 2017. The research team suspects that the improved detection provided by DBT may have led to the decline in ultrasound-only detected lesions in subsequent years.

The biopsy rate did decrease steadily over the five-year period, from 2.9 percent to 1 percent in 2017. PPV for biopsy fluctuated in the study period, jumping 15 percent in the first year, declining slightly over the following two years, then increasing again in the final year, ultimately rising from 5 percent to 22.3 percent. This suggests that biopsies were employed more efficiently over the course of the five-year period.

 

Related Content:

VIDEO: Women Benefit From Mammography Screening Beyond Age 75

VIDEO: How Contrast-Enhanced Mammography Will Impact Breast Imaging

Related Content

More complex, longer interventional procedures such as structural heart interventions or this revascularization of a coronary chronic total occlusion (CTO) at Henry Ford Hospital in Detroit, requires angiography imaging systems that have improved image detail and lower radiation dose. However, purchase of new systems was put on hold by many hospitals in 2020 due to the sudden drop in elective procedures and diversion of resources due to the COVID-19. Photo by Dave Fornell.

More complex, longer interventional procedures such as structural heart interventions or this revascularization of a coronary chronic total occlusion (CTO) at Henry Ford Hospital in Detroit, requires angiography imaging systems that have improved image detail and lower radiation dose. However, purchase of new systems was put on hold by many hospitals in 2020 due to the sudden drop in elective procedures and diversion of resources due to the COVID-19. Photo by Dave Fornell.

Feature | Angiography | January 19, 2021 | By Bhvita Jani
January 19, 2021 – With the postponement of non-essential elective surgeries and medical procedures in 2020 to conser
Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases, NIH

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Image courtesy of  National Institute of Allergy and Infectious Diseases (NIH)

News | Coronavirus (COVID-19) | January 15, 2021
January 15, 2021 — In one of the first studies to examine the impact of the...
A, Contrast-enhanced axial T1-weighted fat-saturated image from baseline MRI before initiation of neoadjuvant therapy shows irregular mass (arrow) in upper inner right breast corresponding to biopsy-proven carcinoma. B, Contrast-enhanced axial T1-weighted fat-saturated image from follow-up MRI performed 3 months after initiation of neoadjuvant therapy shows decrease in size of right breast cancer (arrow). C, Contrast-enhanced axial T1-weighted fat-saturated image 3 months after initiation of neoadjuvant the

A, Contrast-enhanced axial T1-weighted fat-saturated image from baseline MRI before initiation of neoadjuvant therapy shows irregular mass (arrow) in upper inner right breast corresponding to biopsy-proven carcinoma. B, Contrast-enhanced axial T1-weighted fat-saturated image from follow-up MRI performed 3 months after initiation of neoadjuvant therapy shows decrease in size of right breast cancer (arrow). C, Contrast-enhanced axial T1-weighted fat-saturated image 3 months after initiation of neoadjuvant therapy shows new mass (arrow) in upper outer left breast that was assessed as BI-RADS 4. Pathologic examination from MRI-guided core biopsy of new suspicious mass revealed benign usual ductal hyperplasia. No atypia or malignancy was identified. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | MRI Breast | January 15, 2021
January 15, 2021 — According to ARRS' ...
A targeted intervention providing mammograms to hospitalized Medicaid patients can help patients complete overdue breast cancer screening

Getty Images

News | Mammography | January 14, 2021
January 14, 2021 — Completing cancer screening tests, such as...
DB-I website features new educational tools and streamlined user experience to improve access to medically sourced breast density content
News | Breast Density | January 13, 2021
January 13, 2021 — DenseBreast-info.org (DB-I) invites he
This cutting-edge technology assists radiologists in the interpretation of screening mammograms and allows them to diagnose breast cancer earlier and more accurately
News | Mammography | January 12, 2021
January 12, 2021 — Therapixel announced that...
World-first techniques for predicting breast cancer risk from mammograms that were developed in Melbourne could revolutionise breast screening by allowing it to be tailored to women at minimal extra cost

Getty Images

News | Mammography | January 06, 2021
January 6, 2021 — World-first techniques for predicting breast cancer risk from...